Devyser Diagnostics AB
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovaria… Read more
Devyser Diagnostics AB (DVYSR) - Net Assets
Latest net assets as of September 2025: Skr340.90 Million SEK
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has net assets worth Skr340.90 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr459.90 Million) and total liabilities (Skr119.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr340.90 Million |
| % of Total Assets | 74.12% |
| Annual Growth Rate | 50.54% |
| 5-Year Change | 1034.11% |
| 10-Year Change | N/A |
| Growth Volatility | 468.28 |
Devyser Diagnostics AB - Net Assets Trend (2018–2024)
This chart illustrates how Devyser Diagnostics AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Devyser Diagnostics AB (2018–2024)
The table below shows the annual net assets of Devyser Diagnostics AB from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr349.00 Million | -9.37% |
| 2023-12-31 | Skr385.10 Million | -10.74% |
| 2022-12-31 | Skr431.44 Million | +3.54% |
| 2021-12-31 | Skr416.68 Million | +1254.05% |
| 2020-12-31 | Skr30.77 Million | -16.85% |
| 2019-12-31 | Skr37.01 Million | +23.50% |
| 2018-12-31 | Skr29.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Devyser Diagnostics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18055700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.00 Million | 0.29% |
| Other Comprehensive Income | Skr600.00K | 0.17% |
| Other Components | Skr536.50 Million | 153.68% |
| Total Equity | Skr349.10 Million | 100.00% |
Devyser Diagnostics AB Competitors by Market Cap
The table below lists competitors of Devyser Diagnostics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
$80.66 Million |
|
Generalplus Technology Inc
TW:4952
|
$80.67 Million |
|
Fu Chun Shin Machinery Manufacture Co Ltd
TWO:6603
|
$80.72 Million |
|
Spheria Emerging Companies Ltd
AU:SEC
|
$80.72 Million |
|
ELECO PLC LS-01
F:5H3
|
$80.63 Million |
|
402490
KQ:402490
|
$80.63 Million |
|
Lavipharm S.A
AT:LAVI
|
$80.56 Million |
|
RideNow Group, Inc.
NASDAQ:RDNW
|
$80.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Devyser Diagnostics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 385,100,000 to 349,100,000, a change of -36,000,000 (-9.3%).
- Net loss of 61,500,000 reduced equity.
- New share issuances of 23,600,000 increased equity.
- Other comprehensive income decreased equity by 600,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-61.50 Million | -17.62% |
| Share Issuances | Skr23.60 Million | +6.76% |
| Other Comprehensive Income | Skr-600.00K | -0.17% |
| Other Changes | Skr2.50 Million | +0.72% |
| Total Change | Skr- | -9.35% |
Book Value vs Market Value Analysis
This analysis compares Devyser Diagnostics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.98x to 3.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr9.98 | Skr79.60 | x |
| 2019-12-31 | Skr12.20 | Skr79.60 | x |
| 2020-12-31 | Skr10.60 | Skr79.60 | x |
| 2021-12-31 | Skr37.10 | Skr79.60 | x |
| 2022-12-31 | Skr27.10 | Skr79.60 | x |
| 2023-12-31 | Skr23.80 | Skr79.60 | x |
| 2024-12-31 | Skr21.29 | Skr79.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Devyser Diagnostics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.35%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.36x
- Recent ROE (-17.62%) is below the historical average (-8.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 1.73% | 1.08% | 1.00x | 1.61x | Skr-2.48 Million |
| 2019 | 18.94% | 10.90% | 0.87x | 1.99x | Skr3.31 Million |
| 2020 | -35.46% | -16.61% | 0.88x | 2.42x | Skr-13.99 Million |
| 2021 | -4.97% | -22.17% | 0.20x | 1.10x | Skr-62.40 Million |
| 2022 | -10.65% | -36.29% | 0.25x | 1.16x | Skr-89.10 Million |
| 2023 | -13.92% | -31.66% | 0.33x | 1.32x | Skr-92.11 Million |
| 2024 | -17.62% | -28.35% | 0.46x | 1.36x | Skr-96.41 Million |
Industry Comparison
This section compares Devyser Diagnostics AB's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $122,593,500
- Average return on equity (ROE) among peers: -46.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Devyser Diagnostics AB (DVYSR) | Skr340.90 Million | 1.73% | 0.35x | $80.66 Million |
| AroCell AB (AROC) | $222.69 Million | -26.48% | 0.06x | $6.76 Million |
| Genetic Analysis AS (GEAN) | $22.49 Million | -65.66% | 0.88x | $1.89 Million |